Circulating cell-free DNA-based biomarkers for prognostication and disease monitoring in adrenocortical carcinoma

• Published in: European journal of endocrinology Vol. 190; no. 3; pp. 234 - 247
• Main Authors: Lippert, Juliane, Smith, Gabrielle, Appenzeller, Silke, Landwehr, Laura-Sophie, Prete, Alessandro, Steinhauer, Sonja, Asia, Miriam, Urlaub, Hanna, Elhassan, Yasir S, Kircher, Stefan, Arlt, Wiebke, Fassnacht, Martin, Altieri, Barbara, Ronchi, Cristina L
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 02.03.2024
• Subjects: Aggressive behavior; Biomarkers; Carcinoma; Deoxyribonucleic acid; DNA; Nucleotide sequence; ccfDNA; adrenal cancer; liquid biopsy; personalized medicine
• ISSN: 0804-4643; 1479-683X; 1479-683X
• DOI: 10.1093/ejendo/lvae022

Adrenocortical carcinoma (ACC) is a rare aggressive cancer with heterogeneous behaviour. Disease surveillance relies on frequent imaging, which comes with significant radiation exposure. The aim of the study was to investigate the role of circulating cell-free DNA (ccfDNA)-related biomarkers (BMs) for prognostication and monitoring of ACC. We investigated 34 patients with ACC and 23 healthy subjects (HSs) as controls. Circulating cell-free DNA was extracted by commercial kits and ccfDNA concentrations were quantified by fluorimeter (BM1). Targeted sequencing was performed using a customized panel of 27 ACC-specific genes. Leucocyte DNA was used to discriminate somatic variants (BM2), while tumour DNA was sequenced in 22/34 cases for comparison. Serial ccfDNA samples were collected during follow-up in 19 ACC patients (median period 9 months) and analysed in relationship with standard radiological imaging. Circulating cell-free DNA concentrations were higher in ACC than HS (mean ± SD, 1.15 ± 1.56 vs 0.05 ± 0.05 ng/µL, P < .0001), 96% of them being above the cut-off of 0.146 ng/µL (mean HS + 2 SD, positive BM1). At ccfDNA sequencing, 47% of ACC showed at least 1 somatic mutation (positive BM2). A combined ccfDNA-BM score was strongly associated with both progression-free and overall survival (hazard ratio [HR] = 2.63; 95% CI, 1.13-6.13; P = .010, and HR = 5.98; 95% CI, 2.29-15.6; P = .0001, respectively). During disease monitoring, positive BM2 showed the best specificity (100%) and sensitivity (67%) to detect ACC recurrence or progress compared with BM1. ccfDNA-related BMs are frequently detected in ACC patients and represent a promising, minimally invasive tool to predict clinical outcome and complement surveillance imaging. Our findings will be validated in a larger cohort of ACCs with long-term follow-up.